Thromboinflammation

Thrombosis with associated inflammation due to crosstalk between HEMOSTASIS and INNATE IMMUNE RESPONSES modulated by PLATELETS. It is associated with many diseases such as COVID-19; SICKLE CELL ANEMIA; and THROMBOPHLEBITIS.

Also Known As:

Networked: 267 relevant articles (6 outcomes, 19 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Stroke (Strokes)
2.	Pneumonia (Pneumonitis)
3.	Cytokine Release Syndrome
4.	Wounds and Injuries (Trauma)
5.	Ischemic Stroke

Experts

1.	Nilsson, Bo: 11 articles (01/2021 - 01/2013)
2.	Ekdahl, Kristina N: 8 articles (01/2021 - 01/2013)
3.	Chrysanthopoulou, Akrivi: 7 articles (01/2022 - 10/2014)
4.	Ritis, Konstantinos: 7 articles (01/2022 - 10/2014)
5.	Skendros, Panagiotis: 7 articles (01/2022 - 10/2014)
6.	Lambris, John D: 7 articles (12/2021 - 01/2013)
7.	Teramura, Yuji: 6 articles (11/2016 - 01/2013)
8.	Neal, Matthew D: 4 articles (07/2022 - 11/2017)
9.	McGonagle, Dennis: 4 articles (02/2022 - 01/2021)
10.	Mitroulis, Ioannis: 4 articles (01/2022 - 10/2014)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Thromboinflammation:

1.	histidine-rich proteinsIBA 07/01/2016 - "Histidine-Rich Glycoprotein Prevents Septic Lethality through Regulation of Immunothrombosis and Inflammation." 10/01/2018 - "We recently showed that histidine-rich glycoprotein (HRG) supplemental therapy ameliorated septic acute respiratory distress syndrome due to unnecessary neutrophil activation and immunothrombosis formation. " 07/01/2016 - "These results suggested that the supplementary therapy with HRG may provide a novel strategy for the treatment of sepsis through suppression of excessive systemic inflammation and immunothrombosis by keeping circulating neutrophils quiescent and preventing uncontrolled activation of VECs. " 09/01/2020 - "Histidine-rich glycoprotein (HRG), a plasma glycoprotein, ameliorates a septic condition through the suppression of both excess ROS production from neutrophils and immunothrombosis. " 07/01/2016 - "We show that a plasma protein histidine-rich glycoprotein (HRG) was decreased significantly in septic mice with cecal ligation and puncture (CLP) and supplementary treatment of septic mice with exogenous HRG improved survival, with strong inhibition of tight attachment of neutrophils to pulmonary vasculatures, subsequent immunothrombosis, DIC state, lung inflammation, hypercytokinemia, and activation of vascular endothelial cells (VECs). "
2.	Dacarbazine (DIC)FDA LinkGeneric 01/01/2020 - "Although immunothrombosis plays an important role in early host defense, it can lead to DIC and organ failure if dysregulated. " 05/23/2023 - "The pathophysiology of sepsis-associated DIC is multifactorial, and in addition to coagulation activation with suppressed fibrinolysis, multiple inflammatory responses are initiated by activated leukocytes, platelets, and vascular endothelial cells as part of thromboinflammation. " 01/01/2021 - "However, if the infection is sufficiently severe, immunothrombosis disseminates into the systemic circulation, and DIC, which is associated with the endothelial injury, occurs. " 01/01/2021 - "However, the overactivation of neutrophils can promote the formation of immunothrombosis and even cause disseminated intravascular coagulation (DIC), which damages microcirculation. " 01/01/2022 - "During aberrant immunothrombosis, decryption of TF leads to thromboinflammation, sepsis, and DIC. "
3.	Plasma KallikreinIBA 05/01/2015 - "Blocking of plasma kallikrein ameliorates stroke by reducing thromboinflammation." 08/01/2020 - "Mechanistically, kininogen depletion results in reduced plasma kallikrein levels and, during sepsis, in increased intravascular tissue factor that may reinforce immunothrombosis, and thus reduce streptococcal spreading. "
4.	Protein CIBA 09/21/2023 - "Mitigation of Trauma Induced Endotheliopathy by Activated Protein C: A Potential Therapeutic for Post-Injury Thromboinflammation." 05/01/2020 - "COVID-19 hypothesis: Activated protein C for therapy of virus-induced pathologic thromboinflammation."
5.	KininsIBA 04/13/2022 - "Novel contact-kinin inhibitor sylvestin targets thromboinflammation and ameliorates ischemic stroke." 11/01/2016 - "Dangerous liaisons: complement, coagulation, and kallikrein/kinin cross-talk act as a linchpin in the events leading to thromboinflammation."
6.	Glycoproteins (Glycoprotein)IBA 09/01/2020 - "Histidine-rich glycoprotein (HRG), a plasma glycoprotein, ameliorates a septic condition through the suppression of both excess ROS production from neutrophils and immunothrombosis. "
7.	Blood Proteins (Serum Proteins)IBA 07/01/2016 - "We show that a plasma protein histidine-rich glycoprotein (HRG) was decreased significantly in septic mice with cecal ligation and puncture (CLP) and supplementary treatment of septic mice with exogenous HRG improved survival, with strong inhibition of tight attachment of neutrophils to pulmonary vasculatures, subsequent immunothrombosis, DIC state, lung inflammation, hypercytokinemia, and activation of vascular endothelial cells (VECs). "
8.	pseudoginsenoside F11 (PF 11)IBA 10/01/2021 - "Pseudoginsenoside-F11 ameliorates thromboembolic stroke injury in rats by reducing thromboinflammation."
9.	Biomarkers (Surrogate Marker)IBA 12/01/2021 - "To date, few studies have investigated longitudinal changes in immunothrombosis biomarkers in these patients. " 10/01/2023 - "Endothelial, platelet, and erythrocyte microvesicles (MVs) are novel biomarkers of endothelial dysfunction and thromboinflammation. " 01/01/2022 - "Patients with autoimmune chronic inflammatory diseases present increased biomarkers of thromboinflammation and endothelial dysfunction in the absence of flares and cardiovascular comorbidities." 01/01/2023 - "This review integrates both preclinical and clinical studies that highlight sepsis pathophysiology providing a framework for how the development of immunothrombosis could be used as a starting point to investigate biomarkers for early sepsis diagnosis." 01/01/2023 - "This study investigated ARDS development following moderate-to-critical COVID-19 and examined immunothrombosis biomarkers as ARDS predictors. "
10.	Thromboplastin (Tissue Factor)IBA 03/01/2022 - "We highlight recent evidence that platelet activation, platelet-monocyte, and platelet-neutrophil interactions in COVID-19 support pathological thromboinflammation, including in driving tissue factor expression and NETosis, which have been associated with thromboembolic complication and poor outcomes in critically ill patients. " 01/01/2022 - "Platelet-monocyte interaction amplifies thromboinflammation through tissue factor signaling in COVID-19." 01/01/2014 - "Although tissue factor-mediated and NET-mediated immunothrombosis plays a role in early host defense against bacterial dissemination, uncontrolled immunothrombosis may lead to disseminated intravascular coagulation. " 01/01/2021 - "The aim of this study was to investigate the role of tissue factor-enriched NETs in the progression and immunothrombosis of sepsis-induced lung injury. " 01/01/2023 - "Tissue factor expression in monocyte subsets during human immunothrombosis, endotoxemia and sepsis."

Therapies and Procedures

1.	Punctures 07/01/2016 - "We show that a plasma protein histidine-rich glycoprotein (HRG) was decreased significantly in septic mice with cecal ligation and puncture (CLP) and supplementary treatment of septic mice with exogenous HRG improved survival, with strong inhibition of tight attachment of neutrophils to pulmonary vasculatures, subsequent immunothrombosis, DIC state, lung inflammation, hypercytokinemia, and activation of vascular endothelial cells (VECs). "
2.	Ligation 07/01/2016 - "We show that a plasma protein histidine-rich glycoprotein (HRG) was decreased significantly in septic mice with cecal ligation and puncture (CLP) and supplementary treatment of septic mice with exogenous HRG improved survival, with strong inhibition of tight attachment of neutrophils to pulmonary vasculatures, subsequent immunothrombosis, DIC state, lung inflammation, hypercytokinemia, and activation of vascular endothelial cells (VECs). "
3.	Therapeutics 04/17/2023 - "Preclinical data have suggested that intravenous thrombolysis (IVT) before endovascular therapy (EVT) could dampen microvascular thromboinflammation. " 01/01/2023 - "Our data represent initial work in developing cargo-free, anti-platelet therapeutics specifically for conditions of thromboinflammation." 07/20/2022 - "Of special interest is thromboinflammation, key at onset, evolution and therapy of cardiovascular pathology. " 01/01/2022 - "Therefore, developing therapies to target pyroptosis have emerged as an attractive concept to counteract dysregulated immunothrombosis. " 01/01/2022 - "As the relatively new field of immunothrombosis expands at a rapid pace, the focus of academic and pharmacological research has shifted from generating treatments targeted at the traditional 'waterfall' model of coagulation to therapies better directed towards immune components that drive coagulopathies. "
4.	Immunomodulation 02/01/2022 - "By contrast, immunomodulatory therapy has overall benefits in patients with rapid SARS-CoV-2 clearance, via blunting of multifaceted, excessive innate immune responses in the lungs, potentially uncontrolled T-cell responses, possible autoimmune responses, and immunothrombosis. " 01/01/2022 - "These results support the conduct of randomized trials using combined immunomodulation in COVID-19 to target multiple interconnected pathways of immunothrombosis." 02/01/2022 - "In patients with moderate-to-severe COVID-19 pneumonia, an aberrant post-viral alveolitis with excessive inflammatory responses and immunothrombosis underpins use of immunomodulatory therapy (eg, corticosteroids and interleukin-6 receptor antagonism). "
5.	Aftercare (After-Treatment) 01/29/2021 - "We describe a thromboinflammation model which uses straight channels, lined with fixed human umbilical vein endothelial cells, after treatment with tumour necrosis factor-alpha. " 05/01/2023 - "Therefore, we now discuss studies on the association of selected coagulation biomarkers from the hemostasis, inflammation, and immunothrombosis systems with the risk of IS, stroke severity at the acute phase, and clinical outcome after treatment. "